Actavis to buy Forest Labs in $25 billion cash-and-stock drugmaker combination
Actavis PLC plans to buy Forest Laboratories Inc. in an approximately $25 billion deal that will boost the Irish drugmaker's presence in U.S. primary-care doctor offices and bulk up its portfolio of branded drugs.
Actavis will add the Alzheimer's disease treatment Namenda, and newer drugs like the antidepressant Viibryd to its product portfolio with the latest in a string of multi-billion dollar acquisitions that have swelled the drugmaker's size in recent years.
Analyst say the acquisition also gives Actavis more negotiating muscle with hospitals and other care providers that also have grown bigger in recent years.
Actavis said Tuesday it will pay Forest shareholders $26.04 in cash and a portion of an Actavis share for each Forest share. The total, per-share price of $89.48 represents a premium of about 25 per cent over Forest's closing price Friday of $71.39.
Shares of New York-based Forest soared nearly 30 per cent to $92.50 in Tuesday morning trading. That's well above the price Actavis offered, a sign that shareholders believe Forest will receive a better offer. U.S.-traded shares of Dublin-based Actavis climbed 7.6 per cent, or $14.56, to $206.04.
Actavis was formed in 2012 through a $5.6 billion tie-up between generic drugmaker Watson Pharmaceuticals and Actavis Group. It has grown rapidly through acquisitions, including an $8.5 billion deal it closed last fall to buy another Irish drugmaker, Warner Chilcott.
It offers generic drugs and specialty products in areas like urology and women's health. That portfolio includes the osteoporosis treatment Actonel.
New York-based Forest Labs has been squeezed by generic competition to some of its biggest drugs, including its anxiety and depression drug Lexapro. It also faces the loss of patent protection for Namenda in 2015. The company has launched several new drugs, including Viibryd and the lung disease drug Daliresp, to help make up for those losses.
Forest took an annual loss in fiscal 2012, its first in 15 years, and has faced pressure from billionaire investor Carl Icahn, its second-largest shareholder, according to FactSet.
The company has been working to cut costs under new CEO Brent Saunders, who replaced long-standing leader Howard Solomon last fall. The new leader, backed by Icahn, launched plans to cut about 500 jobs as part of a goal to trim $500 million in costs.
Tuesday's announcement comes a few weeks after Forest completed its own acquisition, a $2.9 billion purchase of Aptalis, a company that makes treatments for gastrointestinal problems and cystic fibrosis.
Read more Business News
- Small town reels after killingBC - 7:50 am
- Power out near Silver StarVernon / N. Okanagan - 9:00 am
- Firefighters injured in blazeCanada - 6:56 am
- Freight train derails, 30 deadWorld - 6:46 am
|QHR Technologies Inc||1.23||+0.02|
|Anavex Life Sciences||0.3601||-0.0249|
|Copper Mountain Mining||2.32||-0.06|
|Sunrise Resources Ltd||0.025||-0.005|
|Mission Ready Services||0.26||+0.01|
Our ability to live beyond our years has nothing to do with medical science; we will all live longer than our physical bodies, each of us will leave behind a personal legacy made up of our deeds, our ...
With all of the adventure activities I have done and still do, I wonder sometimes if the edge still exists. The systematic approach to learning a new adventure or extreme activity combined with the r...
How much time should you put into prospecting? The question is a bit of a puzzle. Ideally, there would be a reference book that lists, by industry, how much time you should invest in prospecting acti...